SCHEMBL1744924

SCHEMBL1744924

CC(C)N1CCN(c2cnc(-c3ccc(CNC(=O)OC(C)(C)C)cc3)cn2)CC1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ATR Q13535 1/20 0.41
CKS1B P61024 2/20 0.41
SKP1 P63208 2/20 0.41
SKP2 Q13309 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
ACVR1 Q04771 1/20 0.41
NAMPT P43490 2/20 0.40
MAPT P10636 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
RECQL P46063 1/20 0.40
AKT1 P31749 1/20 0.39
SDCBP O00560 1/20 0.39
SDC2 P34741 1/20 0.39
HRH3 Q9Y5N1 2/20 0.39
PANK3 Q9H999 1/20 0.38
XBP1 P17861 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
GPR55 Q9Y2T6 1/20 0.38
HDAC1 Q13547 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1742562 0.86 SMO (0.46) ATRACVR1MAPTHRH3PANK3
Hydrochloric Acid SCHEMBL3045179 0.85 SMO (0.45) ATRACVR1MAPTHRH3PANK3
SCHEMBL1744923 0.78 PAX8 (0.41) CKS1BSKP1SKP2HRH3
SCHEMBL1743046 0.76 MAPT (0.50) L3MBTL1MAPTPANK3
SCHEMBL3037985 0.76 FYN (0.42) ACVR1HRH3PANK3
SCHEMBL1743218 0.75 HRH3 (0.44) MAPTHRH3
SCHEMBL1742775 0.74 KDM4E (0.46) MAPTPANK3
SCHEMBL1744057 0.74 FYN (0.55) MAPTHRH3TDP1
SCHEMBL27308006 0.74 AOC3 (0.51) CKS1BSKP1SKP2L3MBTL1NAMPT
SCHEMBL3031031 0.74 HRH3 (0.51) HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8846677-B2 Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2014-09-30 US disclosed
US-8501739-B2 Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2013-08-06 US disclosed
US-20120232078-A1 Novel Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2012-09-13 US disclosed
EP-2386554-A1 Compounds active at the histamine H3 receptor High Point Pharmaceuticals, LLC (US) 2011-11-16 EP disclosed
EP-2233470-A1 Histamine H3 receptor antagonists High Point Pharmaceuticals, LLC (US) 2010-09-29 EP disclosed
US-20090312309-A1 Novel Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2009-12-17 US disclosed
EP-1902028-A2 HISTAMINE H3 RECEPTOR ANTAGONISTS Novo Nordisk A/S (DK) 2008-03-26 EP disclosed
WO-2007003604-A2 HISTS1MINE H3 RECEPTOR ANTAGONISTS NOVO NORDISK A/S (DK) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232078-A1 Novel Medicaments HRH3, HRH4, HRH1 ATR 4623/4885CKS1B 1172/4885SKP1 4778/4885
US-20090312309-A1 Novel Medicaments HRH3, HRH4, HRH1 ATR 4623/4885CKS1B 1172/4885SKP1 4778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.